image credit: Adobe Stock

Harvard offshoot 64x Bio nets $55M in series A funding to expand cell production tech

January 19, 2022


64x Bio, a fledgling synthetic cell and gene therapy manufacturer, brought in $55 million in a series A round of fundraising.

The company, which has about 10 employees and was founded in 2020 out of the Harvard Department of Genetics, is focused on addressing cell and gene therapy manufacturing shortfalls highlighted by the COVID-19 pandemic.

Funds from the round will be used to build out the group’s cell line engineering platform dubbed VectorSelect and to hire more employees. The company hopes its technology will yield improved cell lines for a gamut of gene therapies.

Read More on FiercePharma